Cardiovascular toxicities associated with chimeric antigen receptor T-cell therapy
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a groundbreaking immunotherapeutic approach, particularly for oncohematological patients who are refractory to conventional treatments. As clinical trials expand the applications of CAR T-cell therapy beyond hematologic malignancies, a cr...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2025-05-01
|
| Col·lecció: | Frontiers in Pharmacology |
| Matèries: | |
| Accés en línia: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1578157/full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|